Top
Main
 
All Outcomes
 
Feedback
Home
c19early.org COVID-19 treatment researchAntihistamine H1RAsH1RAs (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

Loading...
More

Supplementary Data — Antihistamine H1RAs for COVID-19: real-time meta analysis of 13 studies

@CovidAnalysis, July 2024, Version 8V8
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ACCROS-I Valerio-.. (DB RCT) 61% 0.39 [0.24-0.63] no recov. 61 (n) 40 (n) chlorpheniramine Improvement, RR [CI] Treatment Control ACCROS-I Valerio-.. (DB RCT) 67% 0.33 [0.09-1.24] no recov. 3/61 6/40 chlorpheniramine ACCROS-I Valerio-.. (DB RCT) 89% 0.11 [0.01-0.87] no recov. 1/61 6/40 chlorpheniramine ACCROS-I Valerio-.. (DB RCT) 53% 0.47 [0.22-1.02] no recov. 10/61 14/40 chlorpheniramine ACCROS-I Valerio-.. (DB RCT) 67% 0.33 [0.06-1.71] no recov. 2/61 4/40 chlorpheniramine ACCROS-I Valerio-.. (DB RCT) 59% 0.41 [0.14-1.16] no recov. 5/61 8/40 chlorpheniramine ACCROS-II Valerio-Pascua 54% 0.46 [0.36-0.58] recov. time 330 (n) 330 (n) chlorpheniramine Sanchez-.. (DB RCT) 87% 0.13 [0.01-2.46] hosp. 0/32 2/13 chlorpheniramine Mura (PSM) 25% 0.75 [0.39-1.46] death 88 (n) 88 (n) Salvucci 29% 0.71 [0.51-1.01] PASC 10/14 13/13 LONG COVID Hoertel 58% 0.42 [0.25-0.71] death 138 (n) 7,207 (n) hydroxyzine Vila-Córcoles 53% 0.47 [0.22-1.01] cases Reznikov 34% 0.66 [0.58-0.75] cases n/a n/a Reznikov 37% 0.63 [0.44-0.90] cases n/a n/a Reznikov 17% 0.83 [0.62-1.12] cases n/a n/a Reznikov 48% 0.52 [0.16-1.64] cases n/a n/a Reznikov 52% 0.48 [0.34-0.67] cases n/a n/a Reznikov 43% 0.57 [0.42-0.78] cases n/a n/a Reznikov 62% 0.38 [0.11-1.32] cases n/a n/a Reznikov -33% 1.33 [0.50-3.57] cases n/a n/a Reznikov 34% 0.66 [0.48-0.89] cases n/a n/a Reznikov 26% 0.74 [0.55-0.99] cases n/a n/a Reznikov 35% 0.65 [0.52-0.79] cases n/a n/a Reznikov 14% 0.86 [0.71-1.05] cases n/a n/a Reznikov 74% 0.26 [0.07-1.01] cases n/a n/a Reznikov 78% 0.22 [0.05-1.00] cases n/a n/a Reznikov 36% 0.64 [0.33-1.25] cases n/a n/a Reznikov 8% 0.92 [0.47-1.75] cases n/a n/a Reznikov 59% 0.41 [0.25-0.68] cases n/a n/a Reznikov 29% 0.71 [0.44-1.15] cases n/a n/a Sánchez-Rico 46% 0.54 [0.31-0.89] death 18/164 1,571/14,939 hydroxyzine Monserrat .. (PSM) 80% 0.20 [0.02-0.93] death n/a n/a loratadine Hunt 43% 0.57 [0.49-0.66] death 260/7,600 1,352/18,908 Loucera 40% 0.60 [0.43-0.84] death 251 (n) 15,717 (n) Loucera 30% 0.70 [0.48-1.00] death 251 (n) 15,717 (n) Loucera 51% 0.49 [0.32-0.77] death 233 (n) 15,735 (n) Hoertel -7% 1.07 [0.88-1.31] death 962 (n) 4,810 (n) desloratadine/hydroxyzine Hoertel 8% 0.92 [0.49-1.76] death 11/94 62/470 desloratadine/hydroxyzine Hoertel -9% 1.09 [0.89-1.35] death 104/962 591/4,810 desloratadine/hydroxyzine Antihistamine H1RA COVID-19 outcomes c19early.org July 2024 Favors antihistamine H1RA Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit